Hemispherx BioPharma Stock Price, News & Analysis (NYSEAMERICAN:HEB)

$0.53 +0.04 (+8.87 %)
(As of 02/25/2018 02:56 AM ET)
Previous Close$0.53
Today's Range$0.47 - $0.53
52-Week Range$0.30 - $0.84
Volume927,327 shs
Average Volume766,948 shs
Market Capitalization$18.30 million
P/E Ratio-1.89
Dividend YieldN/A
Beta-0.57

About Hemispherx BioPharma (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-215-9880080

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1.88571428571429
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.28)
Net IncomeN/A
Net Margins-1,391.11%
Return on Equity-49.30%
Return on Assets-32.57%

Miscellaneous

EmployeesN/A
Outstanding Shares36,140,000

Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $0.09 million during the quarter. Hemispherx BioPharma had a negative return on equity of 49.30% and a negative net margin of 1,391.11%. View Hemispherx BioPharma's Earnings History.

Are investors shorting Hemispherx BioPharma?

Hemispherx BioPharma saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,118,922 shares, an increase of 13.7% from the January 12th total of 1,864,347 shares. Based on an average daily volume of 1,222,934 shares, the days-to-cover ratio is currently 1.7 days. Approximately 7.0% of the shares of the stock are sold short.

Who are some of Hemispherx BioPharma's key competitors?

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the folowing people:

  • William M. Mitchell, Chairman of the Board (Age 81)
  • Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel (Age 64)
  • Adam Pascale CPA, Chief Financial Officer (Age 68)
  • Wayne Steven Springate, Senior Vice President - Operations (Age 45)
  • David R. Strayer M.D., Chief Scientific & Medical Officer (Age 70)
  • Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel (Age 65)
  • Stewart L. Appelrouth, Director

How do I buy Hemispherx BioPharma stock?

Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hemispherx BioPharma's stock price today?

One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.53.

How big of a company is Hemispherx BioPharma?

Hemispherx BioPharma has a market capitalization of $18.30 million.

How can I contact Hemispherx BioPharma?

Hemispherx BioPharma's mailing address is One Penn Center 1617 Jfk Blvd, Suite #500, PHILADELPHIA, PA 19103, United States. The specialty pharmaceutical company can be reached via phone at +1-215-9880080.


MarketBeat Community Rating for Hemispherx BioPharma (HEB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hemispherx BioPharma (NYSEAMERICAN:HEB) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Hemispherx BioPharma (NYSEAMERICAN:HEB) Earnings History and Estimates Chart

Earnings by Quarter for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Hemispherx BioPharma (NYSEAMERICAN HEB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017($0.04)$0.09 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.08)$0.21 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.11)$0.08 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.04)$0.02 millionViewN/AView Earnings Details
11/14/2016Q3 16($0.30)$0.02 millionViewN/AView Earnings Details
8/15/2016Q216($0.01)$0.02 millionViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 million$0.04 millionViewN/AView Earnings Details
3/29/2016Q4 2015($0.12)$0.03 millionViewN/AView Earnings Details
11/17/2015Q3 2015($0.24)$0.02 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)$0.05 millionViewN/AView Earnings Details
5/13/2015Q1 15($0.02)$0.04 millionViewN/AView Earnings Details
3/20/2015Q4 2014($0.24)$0.04 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.24)$0.05 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.36)$0.04 millionViewN/AView Earnings Details
5/9/2014Q1 2014($0.24)$0.08 millionViewN/AView Earnings Details
3/14/2014Q4 2013($0.24)$0.04 millionViewN/AView Earnings Details
11/8/2013Q3 2013($0.36)$0.04 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)$0.04 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.24)$0.04 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.36)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.26)ViewN/AView Earnings Details
5/7/2012Q1 2012($0.36)($0.20)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.31)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.24)($0.30)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.36)($0.31)ViewN/AView Earnings Details
5/6/2011Q1 2011($0.24)($0.07)ViewN/AView Earnings Details
3/29/2011Q4 2010($0.36)($0.24)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.36)($0.29)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.36)($0.36)ViewN/AView Earnings Details
5/7/2010Q1 2010($0.36)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.24)($0.36)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.24)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.47)ViewN/AView Earnings Details
5/12/2009Q1 2009($0.47)ViewN/AView Earnings Details
3/16/2009Q4 2008($0.36)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.60)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.48)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.48)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Hemispherx BioPharma (NYSEAMERICAN:HEB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Hemispherx BioPharma (NYSEAMERICAN:HEB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hemispherx BioPharma (NYSEAMERICAN HEB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Hemispherx BioPharma (NYSEAMERICAN HEB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2017Adam PascaleCFOBuy15,873$0.63$9,999.9927,389View SEC Filing  
5/2/2017David R StrayerInsiderBuy7,937$0.63$5,000.3141,804View SEC Filing  
4/27/2017Thomas K EquelsCEOBuy72,464$0.69$50,000.16492,919View SEC Filing  
4/11/2017Thomas K EquelsCEOBuy200,000$0.50$100,000.00420,455View SEC Filing  
2/16/2017Adam PascaleCFOBuy6,981$0.46$3,211.2611,516View SEC Filing  
2/16/2017David R StrayerInsiderBuy9,892$0.46$4,550.3233,867View SEC Filing  
2/16/2017Wayne S SpringateSVPBuy8,014$0.46$3,686.4431,989View SEC Filing  
12/22/2016Thomas K EquelsCEOBuy68,493$0.73$49,999.89220,455View SEC Filing  
11/1/2016Thomas K EquelsCEOBuy10,000$1.00$10,000.00151,962View SEC Filing  
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.001,703,548View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.001,514,548View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.001,484,548View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.001,444,548View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.0030,000View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.001,225,585View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.001,200,585View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Hemispherx BioPharma (NYSEAMERICAN HEB) News Headlines

Source:
DateHeadline
Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio - PR Newswire (press release)
www.prnewswire.com - February 10 at 3:40 PM
Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 13.7%Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 13.7%
www.americanbankingnews.com - February 9 at 8:06 PM
Longtime Philadelphia biotech firm leaves the cityLongtime Philadelphia biotech firm leaves the city
www.bizjournals.com - January 31 at 3:38 PM
Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development ProgramsHemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs
finance.yahoo.com - January 31 at 8:52 AM
Hemispherx to Present at the BIO CEO & Investor ConferenceHemispherx to Present at the BIO CEO & Investor Conference
finance.yahoo.com - January 29 at 8:49 AM
Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-ProtectionHemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection
finance.yahoo.com - January 26 at 3:38 PM
Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint ... - NasdaqHemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint ... - Nasdaq
www.nasdaq.com - January 25 at 3:39 PM
Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint InhibitorsHemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors
finance.yahoo.com - January 25 at 8:45 AM
Hemispherx BioPharma, Inc (HEB) Sees Large Growth in Short InterestHemispherx BioPharma, Inc (HEB) Sees Large Growth in Short Interest
www.americanbankingnews.com - January 24 at 6:08 PM
HEB: Recent Advancements…What Do They Imply?HEB: Recent Advancements…What Do They Imply?
finance.yahoo.com - January 24 at 3:45 PM
Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.
finance.yahoo.com - January 23 at 4:58 PM
Heres Why the 2 Latest Hemispherx BioPharma Announcements Are ImportantHere's Why the 2 Latest Hemispherx BioPharma Announcements Are Important
finance.yahoo.com - January 19 at 3:49 PM
Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production FacilityHemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility
finance.yahoo.com - January 17 at 11:18 AM
Hemispherx Enhances Manufacturing Efficiency of Ampligen - NasdaqHemispherx Enhances Manufacturing Efficiency of Ampligen - Nasdaq
www.nasdaq.com - January 12 at 11:19 AM
Hemispherx Enhances Manufacturing Efficiency of Ampligen - GlobeNewswire (press release)Hemispherx Enhances Manufacturing Efficiency of Ampligen - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:40 PM
Hemispherx BioPharma, Inc (HEB) Short Interest UpdateHemispherx BioPharma, Inc (HEB) Short Interest Update
www.americanbankingnews.com - January 11 at 2:36 AM
Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV - GlobeNewswire (press release)Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV - GlobeNewswire (press release)
globenewswire.com - January 4 at 3:39 PM
Hemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on StockNewsNow.comHemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on StockNewsNow.com
finance.yahoo.com - January 3 at 10:50 AM
Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TVHemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV
finance.yahoo.com - January 2 at 11:06 AM
Hemispherx Biopharma, Inc. to Present at Biotech Showcase ... - GlobeNewswire (press release)Hemispherx Biopharma, Inc. to Present at Biotech Showcase ... - GlobeNewswire (press release)
globenewswire.com - December 30 at 3:39 PM
Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 2.1%Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 2.1%
www.americanbankingnews.com - December 29 at 1:28 AM
ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:41 PM
Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer - GlobeNewswire (press release)Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer - GlobeNewswire (press release)
globenewswire.com - December 20 at 3:38 PM
Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract ManufacturerHemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer
finance.yahoo.com - December 20 at 11:27 AM
ETFs with exposure to Hemispherx Biopharma, Inc. : December 15, 2017ETFs with exposure to Hemispherx Biopharma, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 3:43 PM
Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%
www.americanbankingnews.com - December 11 at 7:58 PM
ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 1:02 PM
Hemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in NovemberHemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in November
www.americanbankingnews.com - November 28 at 1:04 AM
Hemispherx BioPharma, Inc (HEB) Releases  Earnings ResultsHemispherx BioPharma, Inc (HEB) Releases Earnings Results
www.americanbankingnews.com - November 16 at 6:44 PM
Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)
globenewswire.com - November 16 at 4:02 PM
Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TVHemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV
feeds.benzinga.com - November 15 at 9:57 AM
HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?
finance.yahoo.com - November 14 at 3:51 PM

SEC Filings

Hemispherx BioPharma (NYSEAMERICAN:HEB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Hemispherx BioPharma (NYSEAMERICAN:HEB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Hemispherx BioPharma (NYSEAMERICAN HEB) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.